Doxorubicin downregulates cell cycle regulatory hub genes in breast cancer cells.
Breast cancer
Differentially expressed genes
Doxorubicin
Hub genes
Meta-analysis
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
08 Aug 2024
08 Aug 2024
Historique:
accepted:
29
07
2024
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
8
8
2024
Statut:
epublish
Résumé
Breast cancer (BC) is the leading commonly diagnosed cancer in the world, with complex mechanisms underlying its development. There is an urgent need to enlighten key genes as potential therapeutic targets crucial to advancing BC treatment. This study sought to investigate the influence of doxorubicin (DOX) on identified key genes consistent across numerous BC datasets obtained through bioinformatic analysis. To date, a meta-analysis of publicly available coding datasets for expression profiling by array from the Gene Expression Omnibus (GEO) has been carried out. Differentially Expressed Genes (DEGs) identified using GEO2R revealed a total of 23 common DEGs, including nine upregulated genes and 14 downregulated genes among the datasets of three platforms (GPL570, GPL6244, and GPL17586), and the commonly upregulated DEGs, showed significant enrichment in the cell cycle in KEGG analysis. The top nine genes, NUSAP1, CENPF, TPX2, PRC1, ANLN, BUB1B, AURKA, CCNB2, and CDK-1, with higher degree values and MCODE scores in the cytoscape program, were regarded as hub genes. The hub genes were activated in disease states commonly across all the subclasses of BC and correlated with the unfavorable overall survival of BC patients, as verified by the GEPIA and UALCAN databases. qRT-PCR confirmed that DOX treatment resulted in reduced expression of these genes in BC cell lines, which reinforces the evidence that DOX remains an effective drug for BC and suggests that developing modified formulations of doxorubicin to reduce toxicity and resistance, could enhance its efficacy as an effective therapeutic option for BC.
Identifiants
pubmed: 39115587
doi: 10.1007/s12032-024-02468-5
pii: 10.1007/s12032-024-02468-5
doi:
Substances chimiques
Doxorubicin
80168379AG
Antibiotics, Antineoplastic
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
220Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast Off J Eur Soc Mastology. 2022;66:15–23.
Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA. Subtypes of breast cancer. Breast cancer internet [Internet]. Exon Publications; 2022 [cited 2023 Jul 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK583808/
Ashok G, Ramaiah S. A critical review of datasets and computational suites for improving cancer theranostics and biomarker discovery. Med Oncol. 2022;39:206.
pubmed: 36175717
doi: 10.1007/s12032-022-01815-8
Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, et al. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res. 2011;13:R125.
pubmed: 22132754
pmcid: 3326567
doi: 10.1186/bcr3071
Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther. 2017;175:91–106.
pubmed: 28216025
doi: 10.1016/j.pharmthera.2017.02.037
Guo H, Zou J, Zhou L, Zhong M, He Y, Huang S, et al. NUSAP1 promotes gastric cancer tumorigenesis and progression by stabilizing the YAP1 protein. Front Oncol. 2021;10:591698.
pubmed: 33489890
pmcid: 7817543
doi: 10.3389/fonc.2020.591698
Qiu J, Xu L, Zeng X, Wu Z, Wang Y, Wang Y, et al. NUSAP1 promotes the metastasis of breast cancer cells via the AMPK/PPARγ signaling pathway. Ann Transl Med. 2021;9:1689.
pubmed: 34988198
pmcid: 8667124
doi: 10.21037/atm-21-5517
Li M, Yang B. Prognostic value of NUSAP1 and its correlation with immune infiltrates in human breast cancer. Crit Rev Eukaryot Gene Expr. 2022;32:45–60.
pubmed: 35695609
doi: 10.1615/CritRevEukaryotGeneExpr.2021040248
Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere protein F (CENPF) serves as a potential prognostic biomarker and target for human hepatocellular carcinoma. J Cancer. 2021;12:2933–51.
pubmed: 33854594
pmcid: 8040902
doi: 10.7150/jca.52187
Li M-X, Zhang M-Y, Dong H-H, Li A-J, Teng H-F, Liu A-L, et al. Overexpression of CENPF is associated with progression and poor prognosis of lung adenocarcinoma. Int J Med Sci. 2021;18:494–504.
pubmed: 33390818
pmcid: 7757141
doi: 10.7150/ijms.49041
Mi Y-J, Gao J, Xie J-D, Cao J-Y, Cui S-X, Gao H-J, et al. Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma. Dis Esophagus. 2013;26:636–43.
pubmed: 23163484
doi: 10.1111/dote.12002
O’Brien SL, Fagan A, Fox EJP, Millikan RC, Culhane AC, Brennan DJ, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer. 2007;120:1434–43.
pubmed: 17205517
pmcid: 4972098
doi: 10.1002/ijc.22413
Nair G, Hema Sree GNS, Saraswathy GR, Marise VLP, Krishna Murthy TP. Application of comprehensive bioinformatics approaches to reconnoiter crucial genes and pathways underpinning hepatocellular carcinoma: a drug repurposing endeavor. Med Oncol. 2021;38:145.
pubmed: 34687371
doi: 10.1007/s12032-021-01576-w
Zhuo Y-J, Xi M, Wan Y-P, Hua W, Liu Y-L, Wan S, et al. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer. Int J Mol Med. 2015;35:966–72.
pubmed: 25647485
doi: 10.3892/ijmm.2015.2086
Hsu P-K, Chen H-Y, Yeh Y-C, Yen C-C, Wu Y-C, Hsu C-P, et al. TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma. J Gastroenterol. 2014;49:1231–40.
pubmed: 23963785
doi: 10.1007/s00535-013-0870-6
Koike Y, Yin C, Sato Y, Nagano Y, Yamamoto A, Kitajima T, et al. TPX2 is a prognostic marker and promotes cell proliferation in neuroblastoma. Oncol Lett. 2022;23:1–9.
doi: 10.3892/ol.2022.13256
Liang B, Jia C, Huang Y, He H, Li J, Liao H, et al. TPX2 level correlates with hepatocellular carcinoma cell proliferation, apoptosis, and EMT. Dig Dis Sci. 2015;60:2360–72.
pubmed: 26025609
doi: 10.1007/s10620-015-3730-9
Jiang Y, Liu Y, Tan X, Yu S, Luo J. TPX2 as a novel prognostic indicator and promising therapeutic target in triple-negative breast cancer. Clin Breast Cancer. 2019;19:450–5.
pubmed: 31494045
doi: 10.1016/j.clbc.2019.05.012
Chen G, Yu M, Cao J, Zhao H, Dai Y, Cong Y, et al. Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis. Bioengineered. 2021;12:5149–61.
pubmed: 34384030
pmcid: 8806858
doi: 10.1080/21655979.2021.1960775
Li X, Li J, Xu L, Wei W, Cheng A, Zhang L, et al. CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1. J Exp Clin Cancer Res. 2022;41:149.
pubmed: 35449080
pmcid: 9027050
doi: 10.1186/s13046-022-02362-w
Wu F, Shi X, Zhang R, Tian Y, Wang X, Wei C, et al. Regulation of proliferation and cell cycle by protein regulator of cytokinesis 1 in oral squamous cell carcinoma. Cell Death Dis. 2018;9:1–12.
doi: 10.1038/s41419-018-0618-6
Yun HJ, Cho Y-H, Moon Y, Park YW, Yoon H-K, Kim Y-J, et al. Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. Exp Mol Med. 2008;40:345–53.
pubmed: 18587273
pmcid: 2679296
doi: 10.3858/emm.2008.40.3.345
Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38:1043–8.
pubmed: 16921376
doi: 10.1038/ng1861
Chuang HY, Ou YH. Abstract 4068: overexpression of anillin in colorectal cancer promotes the cell proliferation, cell mobility and cell invasion. Cancer Res. 2014;74:4068.
doi: 10.1158/1538-7445.AM2014-4068
Jia H, Yu F, Li B, Gao Z. Actin-binding protein anillin promotes the progression of gastric cancer in vitro and in mice. J Clin Lab Anal. 2020;35:e23635.
pubmed: 33089886
pmcid: 7891526
doi: 10.1002/jcla.23635
Wang D, Naydenov NG, Dozmorov MG, Koblinski JE, Ivanov AI. Anillin regulates breast cancer cell migration, growth, and metastasis by non-canonical mechanisms involving control of cell stemness and differentiation. Breast Cancer Res. 2020;22:3.
pubmed: 31910867
pmcid: 6947866
doi: 10.1186/s13058-019-1241-x
Magnusson K, Gremel G, Rydén L, Pontén V, Uhlén M, Dimberg A, et al. ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer. BMC Cancer. 2016;16:904.
pubmed: 27863473
pmcid: 5116155
doi: 10.1186/s12885-016-2923-8
Zhang L-H, Wang D, Li Z, Wang G, Chen D-B, Cheng Q, et al. Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2021;20:337–44.
pubmed: 32933876
doi: 10.1016/j.hbpd.2020.08.007
Koyuncu D, Sharma U, Goka ET, Lippman ME. Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival. Breast Cancer Res Treat. 2021;185:331–41.
pubmed: 33130993
doi: 10.1007/s10549-020-05962-2
Chen J, Liao Y, Fan X. Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis. Expert Rev Anticancer Ther. 2021;21:795–803.
pubmed: 33764838
doi: 10.1080/14737140.2021.1908132
Tian J-H, Mu L-J, Wang M-Y, Zeng J, Long Q-Z, Guan B, et al. BUB1B promotes proliferation of prostate cancer via transcriptional regulation of MELK. Anti-Cancer Agents Med Chem- Anti-Cancer Agents. 2020;20:1140–6.
doi: 10.2174/1871520620666200101141934
Al-Khafaji ASK, Marcus MW, Davies MPA, Risk JM, Shaw RJ, Field JK, et al. AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 2017;13:4463.
pubmed: 28588715
pmcid: 5452881
doi: 10.3892/ol.2017.6012
Goos JACM, Coupe VMH, Diosdado B, Delis-Van Diemen PM, Karga C, Beliën JAM, et al. Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. Br J Cancer. 2013;109:2445–52.
pubmed: 24104968
pmcid: 3817339
doi: 10.1038/bjc.2013.608
Schneider MA, Christopoulos P, Muley T, Warth A, Klingmueller U, Thomas M, et al. AURKA, DLGAP5, TPX2, KIF11 and CKAP5: five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. Int J Oncol. 2017;50:365–72.
pubmed: 28101582
pmcid: 5238780
doi: 10.3892/ijo.2017.3834
Kahl I, Mense J, Finke C, Boller A-L, Lorber C, Győrffy B, et al. The cell cycle-related genes RHAMM, AURKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients. J Cell Biochem. 2022;123:581–600.
pubmed: 35014077
doi: 10.1002/jcb.30205
Yang G, Chen Q, Xiao J, Zhang H, Wang Z, Lin X. Identification of genes and analysis of prognostic values in nonsmoking females with non-small cell lung carcinoma by bioinformatics analyses. Cancer Manag Res. 2018;10:4287–95.
pubmed: 30349363
pmcid: 6183654
doi: 10.2147/CMAR.S174409
Li R, Jiang X, Zhang Y, Wang S, Chen X, Yu X, et al. Cyclin B2 overexpression in human hepatocellular carcinoma is associated with poor prognosis. Arch Med Res. 2019;50:10–7.
pubmed: 31101236
doi: 10.1016/j.arcmed.2019.03.003
Aljohani AI, Toss MS, El-Sharawy KA, Mirza S, Ball GR, Green AR, et al. Upregulation of cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion. Am J Cancer Res. 2022;12:469–89.
pubmed: 35261781
pmcid: 8899993
Cao J, Sun S, Min R, Li R, Fan X, Han Y, et al. Prognostic significance of CCNB2 expression in triple-negative breast cancer. Cancer Manag Res. 2021;13:9477–87.
pubmed: 35002325
pmcid: 8728388
doi: 10.2147/CMAR.S339105
Xi Q, Huang M, Wang Y, Zhong J, Liu R, Xu G, et al. The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer. Tumor Biol. 2015;36:4939–48.
doi: 10.1007/s13277-015-3141-8
Yang W, Cho H, Shin H-Y, Chung J-Y, Kang ES, Lee E, et al. Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer. Oncotarget. 2016;7:49481–97.
pubmed: 27385216
pmcid: 5226523
doi: 10.18632/oncotarget.10373
Huang Z, Shen G, Gao J. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2. Clin Transl Oncol. 2021;23:1743–51.
pubmed: 33721187
doi: 10.1007/s12094-021-02575-z
Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, et al. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol. 2008;19:68–72.
pubmed: 17956886
doi: 10.1093/annonc/mdm358